Literature DB >> 17259910

Complete blood cell count as a surrogate CD4 cell marker for HIV monitoring in resource-limited settings.

Ray Y Chen1, Andrew O Westfall, J Michael Hardin, Cassandra Miller-Hardwick, Jeffrey S A Stringer, James L Raper, Sten H Vermund, Eduardo Gotuzzo, Jeroan Allison, Michael S Saag.   

Abstract

BACKGROUND: A total lymphocyte count (TLC) of 1200 cells/mL has been used as a surrogate for a CD4 count of 200 cells/microL in resource-limited settings with varying results. We developed a more effective method based on a decision tree algorithm to classify subjects.
METHODS: A decision tree was used to develop models with the variables TLC, hemoglobin, platelet count, gender, body mass index, and antiretroviral treatment status of subjects from the University of Alabama at Birmingham (UAB) observational database. Models were validated on data from the Birmingham Veterans Affairs Medical Center (BVAMC) and Zambia, with primary decision trees also generated from these data.
RESULTS: A total of 1189 patients from the UAB observational database were included. The UAB decision tree classified a CD4 count < or =200 cells/microL as better than a TLC cut-point of 1200 cells/mL, based on the area under the curve of the receiver-operator characteristic curve (P < 0.0001). When applied to data from the BVAMC and Zambia, the UAB-based decision tree performed better than the TLC cut-point of 1200 cells/mL (BVAMC: P < 0.0001; Zambia: P = 0.0009) but worse than a decision tree based on local data (BVAMC: P < or = 0.0001; Zambia: P < or = 0.0001).
CONCLUSION: A decision tree algorithm based on local data identifies low CD4 cell counts better than one developed from a different population or a TLC cut-point of 1200 cells/mL.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17259910     DOI: 10.1097/QAI.0b013e318032385e

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  5 in total

1.  Construction of Machine Learning Models to Predict Changes in Immune Function Using Clinical Monitoring Indices in HIV/AIDS Patients After 9.9-Years of Antiretroviral Therapy in Yunnan, China.

Authors:  Bingxiang Li; Mingyu Li; Yu Song; Xiaoning Lu; Dajin Liu; Chenglu He; Ruixian Zhang; Xinrui Wan; Renning Zhang; Ming Sun; Yi-Qun Kuang; Ya Li
Journal:  Front Cell Infect Microbiol       Date:  2022-05-12       Impact factor: 6.073

2.  Selected hematologic and biochemical measurements in African HIV-infected and uninfected pregnant women and their infants: the HIV Prevention Trials Network 024 protocol.

Authors:  Kasonde Mwinga; Sten H Vermund; Ying Q Chen; Anthony Mwatha; Jennifer S Read; Willy Urassa; Nicole Carpenetti; Megan Valentine; Robert L Goldenberg
Journal:  BMC Pediatr       Date:  2009-08-07       Impact factor: 2.125

3.  Comparison of CD4 cell count, viral load, and other markers for the prediction of mortality among HIV-1-infected Kenyan pregnant women.

Authors:  Elizabeth R Brown; Phelgona Otieno; Dorothy A Mbori-Ngacha; Carey Farquhar; Elizabeth M Obimbo; Ruth Nduati; Julie Overbaugh; Grace C John-Stewart
Journal:  J Infect Dis       Date:  2009-05-01       Impact factor: 5.226

4.  An Evaluation of Alternative Markers to Guide Initiation of Anti-retroviral Therapy in HIV-Infected Children in Settings where CD4 Assays are not Available.

Authors:  Minke H W Huibers; Peter Moons; Nelson Maseko; Montfort B Gushu; Ferdinand W Wit; Steve M Graham; Michael Boele van Hensbroek; Job C Calis
Journal:  J Trop Pediatr       Date:  2015-10-21       Impact factor: 1.165

5.  Prioritizing CD4 count monitoring in response to ART in resource-constrained settings: a retrospective application of prediction-based classification.

Authors:  Livio Azzoni; Andrea S Foulkes; Yan Liu; Xiaohong Li; Margaret Johnson; Collette Smith; Adeeba Bte Kamarulzaman; Julio Montaner; Karam Mounzer; Michael Saag; Pedro Cahn; Carina Cesar; Alejandro Krolewiecki; Ian Sanne; Luis J Montaner
Journal:  PLoS Med       Date:  2012-04-17       Impact factor: 11.069

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.